Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Teva UK has introduced Dorzolamide/Timolol 20mg/5mg per ml ophthalmic solution, indicated for the treatment of elevated intra-ocular pressure (IOP) in patients with open-angle glaucoma or pseudo-exfoliative glaucoma when topical beta-blocker monotherapy is not sufficient.
Subscribe to our email newsletter
Teva UK said that its Dorzolamide/Timolol 20mg/5mg per ml ophthalmic solution is a generic version of Merck Sharp & Dohme’s Cosopt.
Dorzolamide HCl /Timolol Maleate ophthalmic solution is the combination of a topical carbonic anhydrase inhibitor and a topical beta-adrenergic receptor blocking agent.
Dorzolamide hydrochloride is described chemically as: (4S-trans)-4-(ethylamino)-5,6-dihydro-6-methyl-4Hthieno[2,3-b]thiopyran-2-sulfonamide 7,7-dioxide monohydrochloride. Dorzolamide Hydrochloride is optically active.
Teva UK commercial director Kim Innes said that they are pleased to add this product to product portfolio.